FBRX · As filed with the SEC
Forte Biosciences balance sheet, by fiscal year
The statement as Forte Biosciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 76,957,000 | 22,244,000 | 37,125,000 | 41,100,000 | 42,044,000 | 58,765,000 | 8,986,000 | 40,813,000 |
| Marketable securities | — | — | — | — | — | — | 12,835,000 | 55,273,000 |
| Short-term investments | — | 36,121,000 | — | — | — | — | — | — |
| Prepaid expenses and other current assets | 3,632,000 | 2,981,000 | 1,202,000 | 411,000 | 476,000 | 1,133,000 | 1,135,000 | 1,662,000 |
| Total current assets | 80,589,000 | 61,346,000 | 38,327,000 | 41,511,000 | 42,520,000 | 59,898,000 | 22,956,000 | 97,748,000 |
| Property and equipment, net | 129,000 | 77,000 | 109,000 | — | — | 97,000 | 1,689,000 | 3,973,000 |
| Operating lease right-of-use asset | — | — | — | — | — | — | 3,515,000 | — |
| Other assets | 2,061,000 | 138,000 | 544,000 | 486,000 | 786,000 | 1,244,000 | — | 1,360,000 |
| Total assets | 82,779,000 | 61,561,000 | 38,980,000 | 41,997,000 | 43,306,000 | 61,239,000 | 28,160,000 | 103,081,000 |
| Liabilities, convertible preferred stock and stockholders' equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | 9,989,000 | 4,879,000 | 1,424,000 | 1,153,000 | 946,000 | 1,240,000 | 3,218,000 | 3,404,000 |
| Accrued liabilities | 10,762,000 | 4,202,000 | 2,242,000 | 2,026,000 | 812,000 | 1,019,000 | 5,242,000 | 13,094,000 |
| Notes payable, current portion | — | — | — | — | — | — | 4,744,000 | — |
| Deferred license revenue | — | — | — | — | — | — | — | 36,000 |
| Total current liabilities | 20,751,000 | 9,081,000 | 3,666,000 | 3,179,000 | 1,758,000 | 2,259,000 | 13,204,000 | 16,534,000 |
| Operating lease liability, net of current portion | — | — | — | — | — | — | 4,027,000 | — |
| Notes payable, net of current portion | — | — | — | — | — | — | — | 26,201,000 |
| Deferred rent, net of current portion | — | — | — | — | — | — | — | 2,201,000 |
| Other long term liabilities | — | — | — | — | — | — | 81,000 | — |
| Income tax payable | 1,037,000 | — | — | — | — | — | — | — |
| Total liabilities | 21,788,000 | — | — | — | — | — | 17,312,000 | 44,936,000 |
| Stockholders’ equity | ||||||||
| Common stock, $0.001 par value: 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 12,948,308 and 6,393,323 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 13,000 | 6,000 | 36,000 | 21,000 | 15,000 | 13,000 | 23,000 | 23,000 |
| Additional paid-in capital | 284,348,000 | 206,461,000 | 153,794,000 | 125,841,000 | 114,698,000 | 110,424,000 | 290,215,000 | 274,029,000 |
| Accumulated other comprehensive income | 3,000 | 11,000 | 4,000 | — | — | — | 10,000 | (23,000) |
| Accumulated deficit | (223,373,000) | (153,998,000) | (118,520,000) | (87,044,000) | (73,165,000) | (51,457,000) | (279,400,000) | (215,884,000) |
| Total stockholders’ equity | 60,991,000 | 52,480,000 | 35,314,000 | 38,818,000 | 41,548,000 | 58,980,000 | 10,848,000 | 58,145,000 |
| Total liabilities and stockholders' equity | 82,779,000 | 61,561,000 | 38,980,000 | 41,997,000 | 43,306,000 | 61,239,000 | 28,160,000 | 103,081,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.